^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ezabenlimab (BI 754091)

    i
    Other names: BI 754091, BI754091, BI-754091
    Company:
    Boehringer Ingelheim
    Drug class:
    PD1 inhibitor
    Related drugs:
    11d
    A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | N=171 --> 57 | Trial completion date: May 2029 --> Jun 2027 | Trial primary completion date: Feb 2029 --> Jun 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154
    16d
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)
    P1, N=119, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    25d
    A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=149, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Feb 2028
    Enrollment closed • Trial completion date
    |
    Keytruda (pembrolizumab) • ezabenlimab (BI 754091) • BI 765179
    25d
    A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Boehringer Ingelheim
    New P1 trial
    |
    ezabenlimab (BI 754091)
    1m
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)
    P1, N=119, Active, not recruiting, Boehringer Ingelheim | Trial completion date: May 2026 --> Feb 2026
    Trial completion date
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    2ms
    A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    ezabenlimab (BI 754091) • BI 765063 • BI 770371
    3ms
    A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer (clinicaltrials.gov)
    P1, N=171, Recruiting, Boehringer Ingelheim | N=94 --> 171 | Trial primary completion date: Jun 2028 --> Feb 2029
    Enrollment change • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154
    3ms
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=97, Recruiting, Boehringer Ingelheim | N=70 --> 97
    Enrollment change
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    4ms
    A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=160, Recruiting, Boehringer Ingelheim | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2027 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ezabenlimab (BI 754091) • BI 765179
    4ms
    A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Boehringer Ingelheim | Phase classification: P1/2 --> P1 | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2025
    Phase classification • Trial completion date • Trial primary completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532) • ezabenlimab (BI 754091)
    5ms
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=70, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2027 --> Sep 2028 | Trial primary completion date: Sep 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    6ms
    KISIMA-02: A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=94, Recruiting, Amal Therapeutics | Trial completion date: Mar 2027 --> May 2029 | Trial primary completion date: Dec 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • VSV-GP154